Status and phase
Conditions
Treatments
Study type
Funder types
Identifiers
About
The purpose of this study is to investigate the efficacy and safety of tacabrutideg compared with investigator's choice (idelalisib plus rituximab [for CLL only] or bendamustine plus rituximab or venetoclax plus rituximab retreatment) in participants with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) previously exposed to both BTK inhibitors (BTKi) and BCL2 inhibitors (BCL2i).
Full description
CLL (chronic lymphocytic leukemia) and SLL (small lymphocytic lymphoma) are slow-growing blood cancers that affect the same type of white blood cell (called B lymphocytes). They are considered different forms of the same disease. CLL mainly occurs in the blood and bone marrow, while SLL mainly affects the lymph nodes.
Tacabrutideg is a type of medicine called a BTK degrader. BTK (Bruton's tyrosine kinase) is a protein that helps cancer cells survive. Tacabrutideg is designed to attach to the BTK protein and tag it for removal, so that the body's own cellular "clean-up" system breaks it down and clears it away. When more BTK is removed from the body, it interferes with the signals needed for the cancer cells to multiply and survive and may also help overcome resistance caused by certain changes in BTK.
The purpose of this study is to test if tacabrutideg is safe and if it works in adults with CLL or SLL. The main goal of the study is to find the amount of time participants live without their disease getting worse after starting the study treatment.
This study has two treatment groups. Participants will be randomly assigned by chance, to one of the treatment groups. Participants and the study doctors will know what treatment is received during the study.
The study will enroll approximately 250 adults at multiple centers worldwide with CLL or SLL. The overall time to participate in this study is 36 months. Participants will make regular visits to the clinic for treatment, health checks, blood tests, and tumor and imaging tests.
Our company, previously known as BeiGene, is now officially BeOne Medicines. Because some of our older studies were sponsored under the name BeiGene, you may see both names used for this study on this website.
Enrollment
Sex
Ages
Volunteers
Inclusion criteria
Exclusion criteria
NOTE: Other protocol defined Inclusion/Exclusion criteria may apply.
Primary purpose
Allocation
Interventional model
Masking
250 participants in 2 patient groups
Loading...
Central trial contact
Study Director
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal